BlackRock
AARD

BlackRock’s Aardvark Therapeutics AARD Stock Holding History

BlackRock’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
187,045
-605,526
-76% -$2.83M ﹤0.01% 4337
2026
Q1 		$2.99M Buy
792,571
+8,141
+1% +$84.4K ﹤0.01% 4016
2025
Q4 		$10.3M Buy
784,430
+474,965
+153% +$5.93M ﹤0.01% 3455
2025
Q3 		$4.11M Buy
309,465
+103,670
+50% +$1.17M ﹤0.01% 3852
2025
Q2 		$2.78M Buy
205,795
+187,019
+996% +$1.93M ﹤0.01% 3967
2025
Q1 		$141K Buy
+18,776
New +$211K ﹤0.01% 4679

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock's AARD Position: Q2 2026 in Review

BlackRock reduced its Aardvark Therapeutics (AARD) stake by 76% in Q2 2026, selling an estimated $2.83M and leaving 187,045 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #4337.

BlackRock first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.3M in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • BlackRock held 187,045 shares of Aardvark Therapeutics worth $1.08M as of Q2 2026.
  • BlackRock sold 605,526 Aardvark Therapeutics shares in Q2 2026, an estimated $2.83M.
  • Aardvark Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4337 holding.
  • BlackRock first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • BlackRock's Aardvark Therapeutics position peaked at $10.3M in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.